2.25
-0.18(-7.41%)
Currency In USD
| Previous Close | 2.43 |
| Open | 2.33 |
| Day High | 2.34 |
| Day Low | 2.19 |
| 52-Week High | 49.58 |
| 52-Week Low | 1.72 |
| Volume | 149,277 |
| Average Volume | 4.77M |
| Market Cap | 7.4M |
| PE | -0.07 |
| EPS | -32.64 |
| Moving Average 50 Days | 4.26 |
| Moving Average 200 Days | 10.91 |
| Change | -0.18 |
If you invested $1000 in BioXcel Therapeutics, Inc. (BTAI) since IPO date, it would be worth $12.75 as of March 13, 2025 at a share price of $2.25. Whereas If you bought $1000 worth of BioXcel Therapeutics, Inc. (BTAI) shares 5 years ago, it would be worth $7.06 as of March 13, 2025 at a share price of $2.25.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
GlobeNewswire Inc.
Mar 11, 2025 11:00 AM GMT
Topline data expected in second half of 2025 to support potential sNDA submission for label expansion of IGALMI® in the home setting Company has $35M of cash following closing of recent equity financing NEW HAVEN, Conn., March 11, 2025 (GLOBE NEWS
BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
GlobeNewswire Inc.
Mar 07, 2025 12:00 PM GMT
Data to support potential sNDA submission for label expansion of IGALMI® in the home setting Topline data expected in second half of 2025 NEW HAVEN, Conn., March 07, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceu
BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering
GlobeNewswire Inc.
Mar 04, 2025 9:15 PM GMT
NEW HAVEN, Conn., March 04, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced the c